REVIEW article

Front. Med., 26 June 2026

Sec. Obstetrics and Gynecology

Volume 13 - 2026 | https://doi.org/10.3389/fmed.2026.1832193

Superficial heat therapy in women’s health

  • 1. Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

  • 2. Endometriosis Centre Charité University Hospital, Berlin, Germany

  • 3. Clinical Department of Obstetrics, Women’s Diseases and Oncological Gynecology, Nicolaus Copernicus University, Bydgoszcz, Poland

  • 4. Department of Gynecology and Obstetrics, Hospital Da Luz Torres De Lisboa, Lisbon, Portugal

  • 5. Department of Neurosciences, Reproductive Sciences and Oral Sciences, University of Naples Federico II, Naples, Italy

  • 6. Head of the Department of Gynecology and Obstetrics, San Martino Hospital, University of Genoa, Genoa, Italy

Abstract

Background and Objective:

Female-specific pain conditions such as dysmenorrhoea, endometriosis, and pain associated with pregnancy, childbirth, and menopause are highly prevalent and frequently impair quality of life. Superficial heat therapy (SHT) has long been used for pain relief and is well established in the management of musculoskeletal pain through mechanisms including vasodilation, improved microcirculation, muscle relaxation, and modulation of peripheral and central nociceptive pathways. This narrative review aims to synthesize current scientific evidence and clinical experience regarding the role of SHT in managing pain across multiple stages of women’s health.

Methods:

A targeted literature search was conducted in PubMed and Scopus for studies published between 2010 and 2026, supplemented by earlier relevant publications. Search terms included “superficial heat therapy,” “thermotherapy,” “heat wrap,” “dysmenorrhoea,” “endometriosis,” “labor pain,” “postpartum pain,” “breastfeeding-related musculoskeletal pain,” and “menopause-related musculoskeletal pain.” Evidence was evaluated and integrated with the authors’ clinical experience.

Results:

Evidence suggests that SHT may provide clinically meaningful pain relief in several female-specific conditions. In dysmenorrhoea and endometriosis-related pelvic pain, SHT has shown analgesic efficacy comparable in some studies to commonly used analgesics. During labor, thermal interventions such as warm compresses are associated with reduced pain perception and improved maternal comfort. In postpartum and breastfeeding contexts, SHT may alleviate lumbopelvic and musculoskeletal pain related to biomechanical stress and prolonged postures. In peri- and postmenopausal women, SHT can reduce musculoskeletal discomfort and improve functional outcomes. Wearable heat patches represent a practical option due to their sustained, controlled heat delivery and compatibility with daily activities.

Conclusion:

SHT represents a safe, non-invasive, and accessible adjunctive modality for the management of abdominal and MSK pain across different stages of women’s lives. Although it should not replace standard pharmacological or surgical treatments, it may complement conventional therapies and support patient self-management strategies. The integration of SHT into routine clinical care may enhance patient self-management, reduce reliance on pharmacological therapies, and improve quality of life across different stages of women’s health. Future well-designed clinical studies are needed to standardize treatment protocols, establish optimal application parameters, and further clarify its role in conditions where current evidence remains limited or largely extrapolated.

Introduction

Pain in women is uniquely complex as it is shaped not only by biological factors, but also by sociocultural dynamics, and female-specific painful conditions such as dysmenorrhoea, endometriosis, pregnancy, childbirth, and menopause are frequently compounded by societal stigma, secrecy, myths and misinformation which contribute to a distorted and long-lasting psychological framing (). Moreover, women’s pain is frequently normalized or minimized, both in clinical settings and in society, leading to underdiagnosis and undertreatment (). The application of superficial heat therapy (SHT) for pain relief in women-related conditions has a long and well-documented history spanning from ancient civilizations to modern clinical practice: Egyptian papyruses describe the use of heated stones and fomentations applied to the abdomen to alleviate pelvic pain related to menstrual cramps and labor (, ); in 5th century BC Hippocrates of Kos recommended warm compresses and poultices for “uterine suffocation” and relieve pain associated with menstruation; in the 2nd century AD Galen advocated hot applications to relax the uterus and relieve “painful flux” (); in the 12th century, Hildegard of Bingen recommended warm compresses infused with herbs for “women’s flux and belly pains,” while in traditional Chinese medicine (TCM), SHT including moxibustion, i.e., burning dried Artemisia near the skin, has long been used to treat dysmenorrhoea and support labor by warming meridians and dispelling “cold stagnation” (); medical manuals and handbooks of the 1800s emphasized the application of heat to the lower abdomen to ease uterine cramping during menstruation and labor, and by the early 20th century warm baths became standard obstetric practice for labor pain relief in many hospitals (). Moving on to more modern times, randomized controlled trials (RCTs) have demonstrated that SHT significantly reduces pain severity with an efficacy that is often comparable to that of commonly used analgesics for conditions such as dysmenorrhoea, while a growing body of evidence reports the benefits of SHT as warm water immersion and warm compresses during labor in reducing epidural analgesia use, perineal trauma and overall pain (). From a sociological and cultural point of view, pain and any psychophysical discomfort related to typically female conditions such as labor, postpartum, menstruation, endometriosis and menopause are considered rather inevitable and acceptable, and commonly prescribed pharmacological therapies are not always effective in alleviating or resolving them, pushing women to seek remedies on their own, or to stoically endure such issues with a consequent deterioration in their quality of life (QoL) (, ). The goal of this paper is to evaluate the role of SHT in selected gynecological/obstetric conditions beyond menstruation by reviewing recent literature and sharing clinical practice, to foster a shared understanding among healthcare professionals as well as empower women to make informed decisions about their selfcare.

Methods

Evidence acquisition

This narrative review is based on a targeted literature search conducted in PubMed and Scopus for English-language studies published between 2010 and 2026, complemented by earlier articles when historically or clinically relevant, which included the following key-words: “superficial heat therapy,” “thermotherapy,” “heat wrap,” “dysmenorrhoea,” “endometriosis,” “labor pain,” “postpartum pain,” “breastfeeding-related musculoskeletal (MSK) pain,” and “menopause-related MSK pain” Randomized controlled trials, observational studies, systematic reviews, narrative reviews, and clinical guidelines were included, while conference abstracts, editorials, letters, and studies not directly relevant to the scope of the review were excluded. Titles and abstracts were screened by the authors for relevance, and full texts were assessed when necessary. The quality and strength of the available evidence were evaluated qualitatively according to study design, methodological rigor, sample size, and consistency of findings, and were classified as high, moderate, or low. This preliminary review guided the Authors’ discussion on the role of SHT in managing abdominal, pelvic, and MSK pain associated with the selected conditions, i.e., endometriosis-related pelvic and abdominal pain, premenstrual syndrome (PMS)-related dysmenorrhoea, postpartum pain, breastfeeding-related MSK pain, menopause-related MSK pain and labor pain. For each condition, the authors assessed outcomes from selected studies and integrated their clinical experience to provide clinical interpretation and practical considerations on the implementation of SHT in each specific setting, as presented in the following sections.

Mechanism of action of superficial heat therapy

SHT exerts analgesic effects through multiple, interrelated mechanisms (Figure 1):

FIGURE 1

  • Peripheral Mechanisms

  • Activation of transient receptor potential vanilloid (TRPV) channels: local tissue heating activates thermosensitive TRPV channels promoting vasodilation and improving microcirculation. This facilitates clearance of proinflammatory mediators such as prostaglandins, bradykinin, and histamine, reducing nociceptors sensitisation. Enhanced perfusion also reduces ischemia in muscle and connective tissue, decreasing peripheral nociceptive input (, );

  • Muscle relaxation: SHT decreases muscle spindle sensitivity and increases the extensibility of collagen-rich structures, lowering muscle tone and relieving myofascial contractures, therefore leading to an improved joint and soft tissue mobility and a reduction of the pain originated in hypertonic musculature ();

  • Nociceptor desensitization: thermal stimulation seems to be able to transiently reduces the excitability of peripheral A-delta and C fibers, decreasing nociceptor firing rates and providing immediate analgesia (, ).

  • Central Mechanisms

  • Activation of descending pathways: thermal inputs activate descending analgesic systems from the periaqueductal grey matter (PGM) and rostroventromedial medulla (RVM) which release endogenous opioids, serotonin, and norepinephrine to suppress nociceptive transmission at the spinal cord level ();

  • Autonomic modulation: SHT reduces sympathetic activity while promoting parasympathetic dominance, attenuating the release of stress-related catecholamines and cortisol, and promoting relaxation ();

  • Expectations of benefit and the comforting experience of warmth enhance central pain modulation via cognitive and affective pathways, which activate cortical regions involved in descending inhibition ().

Modes of application of superficial heat therapy

Superficial heat therapy (SHT) can be administered through various modalities, including:

  • Dry heat wraps pads or patches which are chemically or electrically activated devices (e.g., ThermaCare®) whose components reacts to air exposure delivering continuous low-level heat (∼40°C) for 8–12 h ();

  • Moist heat packs containing silica gel or clay immersed in hot water (∼70° C) wrapped in towels and applied for 15–30 min (e.g., Hydrocollator® Moist Heat Packs) ();

  • Wax baths containing a mixture of paraffin and mineral oil heated up to ∼50° C, applied by dipping extremities for 20–30 min (e.g., Parabath® Paraffin Heat Therapy System) ();

  • Hot water bottles filled with water at ∼40° C and applied to affected areas for 15–30 min ();

  • Hydrotherapy by immersion of body parts in water heated to 36–40° C for 15–30 min ();

  • Infrared therapy by means of lamps emitting radiant heat at ∼50 cm distance for 15–20 min (e.g., Philips InfraCare®) ().

Use of superficial heat therapy to alleviate pain in gynecological conditions

Endometriosis-related pelvic and abdominal pain

Endometriosis affects approximately 6–10% of women of reproductive age, and despite increased awareness recent studies reported an average delay of approximately 7 years between symptom onset and definitive diagnosis (). The condition presents with a wide spectrum of symptoms including dysmenorrhoea, dyspareunia, dysuria, dyschezia, cyclical and acyclical pelvic pain, along with bleeding disorders and infertility, leading to emotional well-being and overall impaired QoL (). Mechanisms underlying endometriosis-related pain involve hormonal dysregulation, inflammatory mediators, and neurovascular changes (). Oestrogen reduction along with an increase in prostaglandin F2α (PGF2α) production sensitize peripheral nerve receptors, resulting in a lowered pain threshold and amplified pain experience (). Elevated PGF2α levels stimulate the uterus with increased synthesis and release of oxytocin, which further promotes uterine hypercontractility and constriction of arcuate vessels, and resulting ischemia and hypoxia stimulate pain receptors in a vice circle which perpetuates neuroinflammation (). These mechanisms contribute to a chronic pain cycle that is often resistant to conventional therapies leading to emotional distress and a meaningful impact on overall well-being (). Currently, first-line treatment consists of hormone therapy (HT) and surgery, while pain is being treated with non-steroidal anti-inflammatory drugs (NSAIDs) and, in severe cases, opioids (). However, more than 30% of patients are unable to achieve pain relief from conventional therapies, encouraging these treatment-resistant cohorts to look for alternative therapies (). Several studies and reviews support the use of SHT as a non-pharmacological adjunct in managing endometriosis-related pain. A meta-analysis by Jo J et al. analysed six RCTs on the effect of SHT for menstrual pain highlighting its benefit when compared to acetaminophen or no intervention (). According to the European Society of Human Reproduction and Embryology (ESHRE) given that NSAIDs and HT are the first options to be offered to patients suffering from endometriosis, non-pharmacological treatments for pain should also be discussed to improve overall wellbeing and QoL (). As recently highlighted in a cross-sectional survey by Werner et al. carried out in Germany, Austria, and Switzerland, among 912 women suffering from endometriosis 75.4% reported using self-management strategies, with the most prevalent being rest (91.6%), SHT (91.1%), and exercise (63.3%) (). Similar findings were described by Schwartz et al. in a retrospective evaluation of 574 women of whom 88.7% complained from endometriosis-related pain in the lower abdomen and pelvis, 62.5% reported the use of home remedies and complementary health approaches among which SHT was the most commonly used to get relief followed by rest, massage, homeopathy, phytotherapy, acupuncture and kinesiology ().

Clinical interpretation and practical considerations

  • Despite being not curative, SHT can be seen as a valuable and well-accepted adjunctive therapy to HR in endometriosis, particularly for daily symptom relief, especially in women who prefer to avoid systemic medications or who need additional options to be added to NSAIDs, and painkillers.

  • Topical application of heat is considered safe, as it does not exacerbate underlying lesions or inflammation which are typical of the condition.

  • Discreet, wearable heat patches (e.g., ThermaCare®) are preferred over traditional methods (e.g., hot water bottles), as they allow mobility and integration into daily life as well as controlled temperature to avoid burnings.

  • SHT is most effective when used proactively during pain episodes in endometriosis, and it may also support emotional comfort and relaxation which play a pivotal role in the overall well-being of these complex cohorts.

PMS-related abdominal pain

Beginning 5–10 days before menstruation, PMS features a constellation of recurrent somatic and affective symptoms that occur during the luteal phase of the menstrual cycle and resolve shortly after menstruation begins (). PMS affects up to 20% of women of reproductive age, with 20–30% of this population experiencing moderate to severe psychological symptoms that significantly impair their daily functioning such as mood lability, anxiety, difficulty concentrating, sleep disturbances, and fatigue alongside with somatic symptoms, i.e., abdominal discomfort, breast tenderness, headache, myalgia, and a general sense of physical distress which is distinct from the cramping pain of dysmenorrhoea (, ). These symptoms likely result from neurohormonal fluctuations, particularly altered sensitivity to normal cycling levels of oestrogen and progesterone, along with modifications in serotonergic neurotransmission (). Management of PMS pain focuses on symptom relief, and first-line interventions include lifestyle modifications such as regular exercise, dietary changes and stress reduction. For moderate to severe mood symptoms, selective serotonin reuptake inhibitors (SSRIs) are considered the most effective pharmacologic option, while in refractory cases and based on patient preference ovulation suppression with HT can be proposed (). SHT can be considered as a treatment option for abdominal discomfort and related MSK pain associated with PMS due to its mechanisms of action, i.e., local vasodilation, increased tissue blood flow, and muscle relaxation, which have primarily been assessed in dysmenorrhoea. RCTs and systematic reviews in dysmenorrhoea populations have demonstrated that SHT reduces pain intensity and improves pressure pain thresholds in the abdominal region, with comparable efficacy to NSAIDs and superior to acetaminophen for short-term relief (). In a recent systematic review Yuan et al. found that HT was likely to reduce pain intensity both during prophylaxis and acute episodes in primary dysmenorrhea and with comparable analgesic efficacy and a superior safety profile compared to NSAIDs, while Akin et al. previously demonstrated that continuous, low-level topical heat wrap therapy was superior to acetaminophen for pain relief in dysmenorrhoea while reducing fatigue and mood swings (, ). Machado et al. showed that thermotherapy reduces pain intensity and increases abdominal pressure pain threshold in dysmenorrhoea, suggesting a relevant mechanism which may be relevant to PMS-related abdominal and MSK discomfort ().

Clinical interpretation and practical considerations

  • PMS is a complex syndrome which impairs daily functioning, with a broad spectrum of physical manifestations from bloating-related abdominal discomfort, to mastalgia and MSK aches, along with distressing psychological issues. The control over the physical symptoms of this condition certainly has undeniable positive repercussions on the psychological aspects that are associated with it.

  • The Panel stresses that there are currently no specific published data on the use of SHT in PMS-related abdominal and MSK pain. However, data extrapolation from available research on dysmenorrhoea is reasonable based on the known mechanism of action of SHT. Indeed, studies mainly focus on the use of SHT in menstrual pain, and the underlying principle may indirectly justify its use for PMS-related somatic pain.

  • Therefore, it could be stated that SHT is a reasonable, low-risk, nonpharmacologic option for abdominal and MSK pain associated with PMS, supported by indirect evidence from the available literature on MSK pain and dysmenorrhoea in other populations, and the Panel sees no reason for not using SHT in this clinical context as well, due to its favorable safety profile.

  • On the other hand, the absence of any specific data on this topic encourages the opening of a new and intriguing direction for research to assess the use of SHT also in other unexplored clinical contexts, and dedicated clinical studies are warranted to directly evaluate the efficacy and optimal use of this therapeutic methodology in women with PMS-related abdominal and MSK symptoms.

Labor pain

Labor pain is a multidimensional experience resulting from the integration of physiological, neuroanatomical, and psychological factors. During the first stage of labor, pain originates primarily from uterine contractions and cervical dilatation, which activate both mechano- and chemo-sensitive nociceptors in the uterus and cervix whose signals are transmitted via visceral afferents accompanying sympathetic nerves, entering the spinal cord at T10-L1 levels (). Myometrial ischemia during contractions leads to the release of neurochemical mediators such as bradykinin, prostaglandins, and substance P, which sensitize nociceptors and amplify pain perception (). As labor progresses to the second stage, pain shifts to a somatic origin due to distension and compression of the vagina, perineum, and pelvic floor, and painful signals are transmitted through the pudendal nerve, entering the spinal cord at S2-S4 levels (, ). Psychological factors such as anxiety, fear, and previous labors further modulate pain perception through descending pathways and endogenous opioid systems whose effectiveness varies among individuals, while proinflammatory cytokines and transient hypoxia during labor can enhance nociceptor sensitivity and contribute to pain intensity (). The integration of physical, psychological, and neurochemical factors underscores the need for a multimodal approach to labor pain management (). SHT emerges from available literature as a safe adjunct for labor pain relief, particularly in the first stage, and may help attenuate the transmission and perception of nociceptive signals, promoting local vasodilation, reducing muscle tension, and possibly modulating spinal and supraspinal pain pathways. In the 1980s Khamis et al. observed that when a hot water bag was applied on the abdominal wall of 15 full-term multiparous women for 20 min in the first stage of labor and removed for another 20 min, SHT resulted in a significant increase in uterine activity measured by cardiotocography, concluding that SHT had the potential to safely stimulate labor while aiding in reaching an overall maternal comfort and pain control (). In more recent times the role of SHT in labor and birth outcomes have thoroughly been investigated. Smith et al. carried out a Cochrane review and meta-analysis to examine the evidence on unconventional methods for labor pain management including 14 RCTs for a total of about 2000 women and concluded that massage, SHT and thermal manual methods are effective in reducing pain, length of labor while improving women’s sense of control and overall emotional experience (). These findings were confirmed by another systematic review and meta-analysis by Goswami et al. who examined 10 RCTs on the effect of SHT on pain intensity, and duration of labor, concluding that SHT was significantly effective in reducing pain intensity in the first stage of labor, decreasing its duration and newborns showed better Apgar scores at the 5th minute compared to standard therapies (). These findings have been backed up by a number of experimental studies such as the research by Kaur et al. who evaluated the effectiveness of SHT by means of a hydrocollator pack applied on the lumbo-sacral region of 88 nulliparous parturients for 20 min for 3 times with 1 h interval starting from 4 to 5 cm of cervical dilatation and found that labor pain intensity scores were significantly lower in the experimental group than among controls, and no significant difference were recorded as to any fetal or infant-related safety findings (). Gaheen et al. evaluated the effect of perineal massage, warm compresses and hands on techniques during the second stage of labor on perineal outcomes by randomizing 120 parturients, and pointed out that perineal pain intensity as well as perineal tear were significantly reduced among women who received the described treatment compared to control group (). Similar findings were described by Dahlen et al. who showed that warm compresses applied on the perineum for no longer than 30 min with a 30 to 60 min break significantly reduced third- and fourth-degree tears ().

Clinical interpretation and practical considerations

  • SHT has been successfully used during labor to help women managing pain while increasing comfort, especially during the first stage, emerging as a long-established method that can improve the overall experience.

  • SHT positively stimulates uterine muscle activity, potentially reducing labor time, facilitating relaxation, optimizing perineal outcomes and alleviating postpartum issues.

  • The use of SHT is generally considered safe for the fetus, although superficial heating devices should allow for constant monitoring of the temperature applied.

  • SHT is not recommended during epidural anesthesia, and should not interfere with any obstetric procedures or emergency intervention that may be necessary during labor.

Post-partum pain

Postpartum pain is a frequent, multifactorial condition arising from childbirth-related biomechanical stress, hormonal shifts, neuromuscular dysfunction, and tissue injury (). Although acute perineal and uterine pain typically resolve within weeks, persistent lumbopelvic pain (PLP) localized between the iliac crest, gluteal folds, sometimes radiating to the posterior thigh, and pelvic girdle pain (PGP) particularly near the sacroiliac joints sometimes radiating to the posterior thigh, can impair maternal function and QoL for months to years postpartum (). Several mechanisms underlie postpartum MSK pain and nociceptive syndromes, since high relaxin and progesterone levels induce ligamentous laxity in the sacroiliac and pelvic ligaments, while neuromuscular adaptations and tissue injury contribute to pain persistence. Uterine cramping pain is a common postpartum complaint, resulting from involutional contractions of the uterus. Building on the multimodal framework for other women’s health condition, the most robust evidence for acute uterine cramping pain after vaginal delivery supports the use of NSAIDs as first-line pharmacologic therapy, while acetaminophen may be used as an adjunct though its efficacy is less certain (). For acute perineal pain after vaginal delivery with trauma, cold therapy (i.e., ice packs) is recommended as first-line treatment, while a short course of low-dose epidural morphine may be considered with appropriate monitoring for women with severe perineal trauma (). Nonpharmacologic adjuncts such as SHT in the form of heating pads applied to the lower abdomen are recommended by the American College of Obstetricians and Gynecologists (ACOG) as part of a stepwise approach, particularly for after-birth pain, based on consensus and clinical experience, although the supporting evidence is of low certainty and primarily extrapolated from dysmenorrhoea literature ().

Clinical interpretation and practical considerations

  • For women with persistent lumbopelvic pain localized between the iliac crest and gluteal folds, or pelvic girdle pain near the sacroiliac joints arising post-partum, literature supports a multimodal strategy emphasizing nonpharmacologic interventions.

  • The available evidence supporting the use of SHT in postpartum pain remains limited and is largely extrapolated from studies conducted in dysmenorrhoea and non-specific MSK pain populations. Further well-designed clinical trials are needed to establish its effectiveness, safety, and optimal application protocols in postpartum women. However, SHT may be considered a low-risk adjunct for symptom relief, particularly in combination with other modalities, especially to minimize medication exposure or as part of a patient-centered decision-making approach. SHT should not be used in case of caesarean delivery or during epidural analgesia, and caution should be exercised when using SHT in the first 24–48 h after delivery due to the potential risks of postpartum bleeding and uterine atony. Although SHT does not directly affect coagulation, the immediate postpartum period is characterized by a heightened risk of primary postpartum hemorrhage most commonly due to uterine atony, and the uterus remains highly vascular during this time.

Breastfeeding-related MSK pain

Breastfeeding-related MSK pain is highly prevalent, and recent survey data indicate that up to 84% of breastfeeding mothers experience back pain at least once a month, while nearly half report weekly pain in the cervical, thoracic, or lumbosacral regions (). Dysfunctional states, including moderate disability, are present in over a quarter of those affected, as prolonged breastfeeding sessions with suboptimal positioning, particularly sitting without adequate support, are associated with increased pain intensity, while lying or semi-lying positions with head support are associated with less neck pain (). Breastfeeding-related pain, including MSK discomfort, is a leading cause of early weaning, reduced breastfeeding duration, and it interferes with activities of daily living while negatively affecting QoL (). RCTs and meta-analyses demonstrate that SHT reduces pain and disability in non-specific acute and subacute low back pain (, ). Heat wrap therapy applied for several hours daily over 5–7 days has shown greater pain reduction compared to oral placebo and immediate pain relief, and the addition of exercise to SHT further improved pain and function (). Nadler et al. conducted two RCTs on continuous low-level SHT in individuals with acute non-specific lower back pain and reported significantly greater pain relief than commonly used analgesics (i.e., acetaminophen and ibuprofen) and placebo for up to 16 h, along with improved mobility and reduced muscle stiffness following treatment (). Moreover, additional beneficial outcomes on SHT applied also to other MSK regions, such as the quadriceps, the plantar fascia and the knee, were reported by Petrofsky et al. ().

Clinical interpretation and practical considerations

  • Breastfeeding women frequently complain of MSK pain due to prolonged and unergonomic positions. In addition, MSK pain in this context can be exacerbated by emotional and psychological issues, making new mothers particularly sensitive and vulnerable.

  • A multimodal approach integrating ergonomic support, targeted exercise, safe pharmacologic analgesia, education, and adjunctive SHT can improve maternal comfort, functional capacity, and breastfeeding duration in lactating women during the first 6 months postpartum.

  • Evidence highlighting SHT efficacy in successfully treating non-specific MSK pain arising in other clinical contexts and affecting other body parts might also prove relevant and provide a solid base for implementing this treatment modality in breastfeeding-related MSK discomfort, where static postures and muscle fatigue are common, and patients may prefer to avoid systemic medications.

  • Although there are no contraindications to the application of SHT to the painful area, it is important to avoid contact with the skin of the breast, which is normally tense and sensitive during breastfeeding.

Menopause-related MSK pain

More than 70% of women undergoing the menopause transition will experience MSK symptoms and 25% will develop some degree of disability because of them. Often-unrecognized, menopause-related MSK symptoms involve the neck, shoulders, low back, and the large joints (e.g., knees, hips), contributing to reduced mobility, sleep disturbances, diminished QoL, and women experience a linear increase in moderate to severe MSK pain from pre-menopause through perimenopause to post-menopause (, ). These symptoms, including arthralgia, loss of muscle mass and bone density, and progression of osteoarthritis are largely driven by oestrogen fluctuations and deficiency which increase inflammation and heighten pain sensitivity, and they may be misattributed to aging or other comorbidities delaying correct diagnosis (, ). Management strategies are multidisciplinary and lifestyle interventions are pivotal since regular weight-bearing and resistance exercise are associated with preservation of muscle and bone mass and overall reduction in symptom severity (). Nutritional optimization (i.e., adequate protein, calcium, and vitamin D intake) is essential for bone and muscle health, and conservative measures such as simple analgesia, weight loss, and physical therapy should be encouraged (). HT can be considered for MSK symptoms especially in women < 60 years of age or within 10 years of menopause onset with vasomotor manifestations, while for those with osteoporosis but without any vasomotor symptoms, non-hormonal osteoporosis medications are preferred (). SHT is a safe, low-risk adjunct that provides relief of MSK pain in peri- and postmenopausal women, even though it does not directly address loss of muscle mass or bone density, nor does it modify disease progression. However, SHT (e.g., hot packs, heat wraps, hydrotherapy) is reported to be able to reduce pain intensity and improve function in rheumatic and MSK pain which can accompany several conditions, including menopausal arthralgia and osteoarthritis, with a favorable safety profile ().

Clinical interpretation and practical considerations

  • The clinical picture of menopause is extremely varied, therefore the occurrence of MSK pain in this context often makes part of a wider and more complex syndrome.

  • Since its mechanism of action involves local vasodilation, reduced muscle spasm, and modulation of inflammatory mediators, SHT may be used as part of a multimodal approach for symptomatic pain relief, especially in women with osteoarthritis or chronic joint pain during menopause.

  • Addressing comorbidities which are a feature of the menopause transition such as sleep disturbance, depression, and fatigue, is also important for improving QoL in these cohorts of patients. Furthermore, patients’ education about the MSK syndrome of menopause along with a proactive management is critical to prevent long-term disability.

  • In individuals suffering from hot flushes, the application of SHT may exacerbate or worsen these symptoms. Therefore, SHT should be evaluated on a case-by-case basis especially in patients with vasomotor manifestations.

Safety considerations

To minimize the risk of adverse effects, heat should generally be applied within the range of 38–42 °C, and prolonged continuous use should not exceed 8–12 h when wearable low-level heat devices are used. The main potential adverse effects of SHT include skin irritation, erythema, overheating, discomfort, and burns, particularly when heat is applied for prolonged periods, at excessive temperatures, or over areas with impaired sensation. Therefore, SHT should not be applied over open wounds, inflamed or damaged skin, infected areas, or regions with reduced thermal sensitivity. Patients should be advised to discontinue treatment in case of pain, burning sensation, marked redness, dizziness, or worsening symptoms. In endometriosis-related and PMS-related abdominal pain, SHT may be used as an adjunctive self-management strategy, provided that heat is not applied over damaged or irritated skin. In labor, warm compresses or local heat application may improve maternal comfort, but temperature should be carefully monitored and the intervention should not interfere with obstetric monitoring or emergency procedures. SHT is not recommended during epidural or spinal analgesia because reduced sensation may increase the risk of thermal injury. In the postpartum period, SHT should be used cautiously, particularly during the first 24–48 h after delivery, due to the physiological risk of postpartum bleeding and uterine atony. It should not be applied over caesarean wounds, episiotomy sites, perineal trauma, or any area of damaged tissue. In breastfeeding-related musculoskeletal pain, heat may be applied to the cervical, thoracic, or lumbar regions, but direct application to the breast should be avoided, especially during active breastfeeding, and infant skin contact with heated devices should be prevented. Finally, in peri- and postmenopausal women, SHT should be considered on a case-by-case basis in women with vasomotor symptoms, as heat exposure may exacerbate hot flushes.

Conclusion

Superficial heat therapy (SHT) emerges as a clinically relevant, non-invasive, and accessible modality with a robust documented efficacy to manage MSK and abdominal pain across a spectrum of gynecological and obstetric conditions (Table 1). SHT modulates pain through peripheral, spinal, and central mechanisms, offering a multidimensional approach in clinical settings such as dysmenorrhoea, endometriosis, PMS-related pain, labor and postpartum pain, breastfeeding and menopause-related MSK pain. The integration of SHT into routine clinical care represents a patient-centered approach that is especially valuable given the limitations and side effects of long-term pharmacologic therapies. Heating modalities such as wearable patches provide prolonged and discreet relief, aligning well with the daily demands of women in various life stages. Importantly, SHT also supports self-management strategies and empowers women to take active roles in their health, potentially improving their QoL and reducing healthcare burden. Future research should aim to standardize SHT protocols across indications, assess long-term outcomes, patient adherence, cost-effectiveness in diverse healthcare settings, and explore new clinical settings where this treatment modality might be applicable.

TABLE 1

ConditionExpected benefitsRecommended temperature and applicationDuration/ frequencyContraindications/ warningsEvidence levelClinical notes
EndometriosisRelief of pelvic and abdominal pain; muscle relaxation38–40 °C8–12 h continuous useAvoid on inflamed or damaged skinModerateAdjunctive use only; compatible with daily activities
PMS-related painReduction of cramps and MSK discomfort38–42 °C, lower abdomen or lumbar area15–30 min or intermittent daily useNot effective for psychological symptomsLow–Moderate (indirect evidence)Evidence extrapolated from dysmenorrhoea studies
Labour painPain relief during first stage; improved comfortWarm compresses ~40 °C, abdomen, back, perineum20–30 min with intervalsAvoid during epidural/spinal analgesiaModerateMay improve labour outcomes and maternal comfort
Postpartum painRelief of uterine cramps and lumbopelvic discomfort38–40 °C, abdominal or back applicationAfter first 24–48 h postpartumAvoid on surgical wounds or damaged tissueLow (indirect evidence)Use cautiously due to bleeding/uterine atony risk
Breastfeeding-related MSK painRelief of neck, shoulder, and back pain38–42 °C, cervical, thoracic, lumbar areas15–30 min or prolonged low-level applicationAvoid breast area and infant skin contactModerate (extrapolated MSK evidence)Combine with ergonomic education and physiotherapy
Menopause-related MSK painReduction of joint stiffness and pain38–42 °C, major joints, back, knees15–30 min daily or as neededMay worsen hot flushesLow–ModerateBest used within multimodal management

Clinical use of SHT in female-related conditions.

hrs, hours; MSK, musculoskeletal; PMS, pre-menstrual syndrome; NSAIDs, nonsteroidal anti-inflammatory drugs.

Study limitations

Patients’ responses to SHT are variable and influenced by psychological, hormonal, and cultural factors. Moreover, literature search has highlighted that there is a lack of standardized protocols regarding temperature, duration, and frequency of application of this treatment modality, while high-quality RCTs are limited for many gynecological applications of SHT.

Statements

Author contributions

AP: Supervision, Writing – review & editing, Conceptualization, Validation, Writing – original draft. SM: Conceptualization, Validation, Supervision, Writing – review & editing, Writing – original draft. KP: Writing – original draft, Conceptualization, Writing – review & editing, Validation, Supervision. JR: Conceptualization, Supervision, Writing – review & editing, Validation, Writing – original draft. GS: Writing – review & editing, Conceptualization, Validation, Supervision, Writing – original draft. AC: Conceptualization, Validation, Writing – review & editing, Supervision, Writing – original draft.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This publication was supported by an unrestricted grant from Angelini Pharma S.p.A. The sponsor did not play any role in the design, execution, interpretation, or writing of this article.

Acknowledgments

We thank Éthos S.r.l. for their editorial assistance in organizing and providing technical support, as well as Dr Marta Castano, MD, for Medical Writing assistance.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor MD declared a past co-authorship with the author GS.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Summary

Keywords

breastfeeding, dysmenorrhoea, endometriosis, labor pain, menopause, MSK pain, superficial heat therapy, Women’s health

Citation

Puhakka A, Mechsner S, Placek K, Reis JL, Saccone G and Cagnacci A (2026) Superficial heat therapy in women’s health. Front. Med. 13:1832193. doi: 10.3389/fmed.2026.1832193

Received

16 March 2026

Revised

05 June 2026

Accepted

09 June 2026

Published

26 June 2026

Volume

13 - 2026

Edited by

Mattia Dominoni, San Matteo Hospital Foundation (IRCCS), Italy

Reviewed by

Juan Moisés De La Serna, Universidad Internacional De La Rioja (UNIR), Spain

Jawaher Hazza Alharbi, Minster of Health, Saudi Arabia

Updates

Copyright

*Correspondence: Antti Puhakka,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics